Creative Biogene is the first-class company offering the best DNA Methyltransferase (DNMT) screening and profiling service. With years of experience and skills, we have developed a wide range of platforms for a series of DNMTs targets. Creative Biogene will assist you DNMTs-based drug discovery project with the most competitive price and highest data quality.
Creative Biogene offers DNMTs assays, including DNMT1, DNMT3A and DNMT3B, which will be performed by Chemiluminescent or radiolabeled method.
A methyl group from S-adenosyl-methionine (SAM) is transferred to the C5 position of the pyrimidine ring of cytosine residues by DNMTs in genomic CpG dinucleotides. CpG dinucleotides are preferentially located in particular regions in the genome, including clusters in gene promoters called CpG islands. CpG methylation plays a critical role in several aspects, including silencing retrotransposon element sequences (i.e., LINE-1 or Alu repeats), imprinting, X chromosome inactivation, regulating gene expression, and cellular transformation (Jason, et al. 2013).
The process of DNA methylation is controlled at several different levels in normal and diseased cells. A family of enzymes, DNA methyltransferases (DNMTs) carry out the addition of methyl group. Five DNMT isoforms, DNMT1, DNMT2, DNMT3a, DNMT3b, and DNMT3L are in genomic, however only three DNMTs (DNMT1, DNMT3A, and DNMT3B) are involved in the establishment and maintenance of DNA methylation patterns.
It seems that DNMT1 is responsible for the maintenance of established patterns of DNA methylation, while DNMT3A and DNMT3B appear to mediate the establishment of new or de novo DNA methylation patterns. It has been found that in many different diseases, especially in cancers, there is abnormal DNA methylation associated with increased expression or the activity of DNMTs. Inhibition of DNMTs may cause demethylation and expression of silenced genes. Therefore, DNMT inhibitors have been developed as potential anticancer agents.
Fig.1 Repression of gene expression of DNMTs (Ganesan, et al. 2009)
Advantages of DNMTs screening and profiling assays in Creative Biogene:
Inhibitors/activators screening with more than 3 assays
IC50 determination and single point concentration assays
Fast turnaround time
High quality data results
Creative Biogene offers a broad range of services making it easy to screen and profile your compounds against target DNMTs. Creative Biogene is dedicating to ensuring our services on DNMTs profiling are at the highest level of quality. Based on the commitment of prompt communication and on-time reporting, our experienced scientists have confidence in providing a high-efficiency service to meet the strict project timelines.
If you have any special requirements in DNA Methyltransferase assays, please feel free to contact us at email@example.com or 1-631-626-9181. We are looking forward to working together with your attractive projects.
1.Jason, M. F., Mark, K. P., Rebecca, N. N., Suzanna, C., Krzysztof, S., Michael, S., Kevin, W., Thomas, F. H.,, Koc-Kan, H., Michael, V. M., Steven, B. K. (2013) ‘Epigenetic Drug Discovery: Targeting DNA Methyltransferases’, J Biomol Screen., 17(1), 2-17
2.Ganesan, A., Nolan, L., Crabb, S.J., Packham, G. (2009) ‘Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug Discovery’, Current Cancer Drug Targets, 9, 963-981